Table 3.
Half-maximal inhibitory concentrations (IC50; μm, ± SEM) of fenofibrate, selected statins, and glipizide for selected recombinant human cytochrome P450s
| 1A2 | 2B6 | 2C8 | 2C9 | 2C19 | 2D6 | 3A4 | |
|---|---|---|---|---|---|---|---|
| Fenofibrate | >1000 | 0.7 ± 0.2 | 4.8 ± 1.7 | 9.7 ± 40.7 | 0.2 ± 0.1 | >1000 | 142.1 ± 114.3 |
| Atorvastatin | >100 | >50 | 55.7 ± 19.6 | 7.3 ± 0.7 | 81.5 ± 14.9 | >100 | 5.2 ± 1.9 |
| Lovastatin | >100 | >50 | 27.5 ± 1.5 | 6.6 ± 0.6 | 32.7 ± 5.5 | 40 ± 22 | 23.4 ± 5.3 |
| Pravastatin | >1000 | >1000 | >1000 | >1000 | >1000 | >1000 | >1000 |
| Simvastatin | >100 | 46 | 28 ± 13.4 | 8.1 ± 1.3 | 55.8 ± 23.1 | 47 ± 5.7 | 4.8 ± 2.5 |
| Simvastatin acid | >100 | >50 | 76.5 ± 6.2 | 16.5 ± 6 | >100 | >100 | 42.6 ± 4.3 |
| Glipizide | >1000 | >1000 | 338.2 ± 26.8 | 24 ± 7.2 | >1000 | >1000 | 102 ± 33.7 |